Stuart Solomon, MD

Professor of Clinical Cardiology, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist


Dr. Solomon began his clinical cardiology career at the Diagnostic Clinic of Houston in 1983. He is Board Certified in internal medicine with a subspecialty board in cardiovascular disease and a special added qualification in interventional cardiology. Dr. Solomon received his first academic appointment in 1984 as an Instructor of Internal Medicine at The University of Texas Medical School in Houston, Texas. He later joined the faculty at the Baylor College of Medicine in 1999 as a Clinical Associate Professor in the Department of Internal Medicine.

Description of Research

Dr. Solomon has substantial experience in clinical research having served as an investigator or co-investigator on numerous clinical trials.

Areas Of Expertise

Cardiology Investigational new drugs Clinical trails

A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. 12-Month Outcomes From the ENDEAVOR IV Trial
Leon, MB, Mauri, L, Popma, JJ, Cutlip, DE, Nikolsky, E, OShaughnessy, C, Overlie, PA, McLaurin, BT, Solomon, SL, Douglas, JS, Ball, MW, Caputo, RP, Jain, A, Tolleson, TR, Reen, BM, Kirtane, AJ, Fitzgerald, PJ, Thompson, K & Kandzari, DE 2010, Journal of the American College of Cardiology, vol 55, no. 6, pp. 543-554. DOI:

Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions. 2-Year Follow-Up From the ENDEAVOR IV Trial
Leon, MB, Kandzari, DE, Eisenstein, EL, Anstrom, KJ, Mauri, L, Cutlip, DE, Nikolsky, E, OShaughnessy, C, Overlie, PA, Kirtane, AJ, McLaurin, BT, Solomon, SL, Douglas, JS & Popma, JJ 2009, JACC: Cardiovascular Interventions, vol 2, no. 12, pp. 1208-1218. DOI:

Clinical and Angiographic Outcomes in Diabetics From the ENDEAVOR IV Trial. Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
Kirtane, AJ, Patel, R, OShaughnessy, C, Overlie, P, McLaurin, B, Solomon, S, Mauri, L, Fitzgerald, P, Popma, JJ, Kandzari, DE & Leon, MB 2009, JACC: Cardiovascular Interventions, vol 2, no. 10, pp. 967-976. DOI:

Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention
Lev, EI, Tayyan, N, Raizner, AE, Solomon, SL, Simmons, D & Kleiman, NS 2006, Coronary Artery Disease, vol 17, no. 4, pp. 379-384. DOI:

Initial experience with a magnetic navigation system for percutaneous coronary intervention in complex coronary artery lesions
Atmakuri, SR, Lev, EI, Alviar, C, Ibarra, E, Raizner, AE, Solomon, SL & Kleiman, NS 2006, Journal of the American College of Cardiology, vol 47, no. 3, pp. 515-521. DOI:

Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide
Kleiman, NS, Klem, J, Fernandes, LS, Rubin, H, Challa, S, Solomon, S, Maresh, K, Arora, U, Klem, E, Buergler, J, Mathew, S, Browning, A & DeLao, T 2002, American Heart Journal, vol 143, no. 4, pp. 585-593. DOI:

Progressive dehiscence and dynamic compression of an aortic root homograft: Detection and characterization by transesophageal echocardiography
Nagueh, SF, Bozkurt, B, Li, GA, Solomon, SL, Reardon, MJ & Zoghbi, WA 1996, American Heart Journal, vol 132, no. 5, pp. 1070-1073. DOI:

Exercise-induced right ventricular tachycardia and arrhythmogenic right ventricular dysplasia: Electrophysiologic and therapeutic considerations
Solomon, SL, Van Osdol, KD & Massumi, A 1983, Texas Heart Institute Journal, vol 10, no. 4, pp. 351-357.

Cardiogenic acute renal failure (CARF) following open-heart surgery
Barcenas, CG, Jones, P & Solomon, S 1979, Cardiovascular Diseases, vol 6, no. 3, pp. 298-307.